Original source: techcrunch.com — Proximal Ventures raises debut fund to back startups bringing AI to drug development
Proximal Ventures, a new venture capital firm led by former SignalFire investor Sahir Raoof, has raised $27.5 million to invest in startups bringing artificial intelligence (AI) to drug development, according to techcrunch.com. The fund targets early-stage companies aiming to automate and improve the tools, infrastructure, and services that support the pharmaceutical industry.
What happened
Sahir Raoof, previously an executive at two healthcare startups and a principal at SignalFire, has launched his first solo venture capital fund, Proximal Ventures. Despite a challenging fundraising environment for first-time fund managers, Raoof secured $27.5 million to invest in pre-seed and seed-stage startups. The fund will write checks ranging from $500,000 to $1.5 million for companies that use AI to address bottlenecks in pharmaceutical research and development.
Pharmaceutical companies have traditionally relied on specialized service providers for tasks like synthesizing molecular compounds, scaling drug manufacturing, and analyzing clinical trial data. Raoof told techcrunch.com that while pharma has not historically been a major software buyer, it is a strong buyer of services. He believes AI can automate much of this outsourced work, potentially saving time and reducing costs for drug developers.
Proximal Ventures has already invested in seven startups. One example is ChronicleBio, co-founded by former OpenAI executive Fidji Simo, which uses AI to analyze biological and medical data to better understand chronic diseases and identify potential treatments. Other backers of Proximal Ventures include VC firms SignalFire and Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors such as Dimension Capital co-founders Nan Li and Zavain Dar. Amy Abernethy, co-founder of Highlander Health and former principal deputy commissioner of the FDA, is also an investor.
Raoof’s background includes leading business development at clinical trial recruitment startup Iterative Health and overseeing partnerships at Flatiron Health, an oncology data company acquired by Roche for $1.9 billion in 2018. Amy Abernethy, who worked with Raoof at Flatiron, told techcrunch.com that his ability to spot industry bottlenecks and build relationships has helped Proximal invest alongside larger funds.
Why it matters for researchers
The launch of Proximal Ventures’ fund highlights the growing intersection of AI and pharmaceutical services. For researchers in AI and machine learning, this signals increasing demand for expertise that can be applied beyond traditional tech sectors. Startups are now targeting not only drug discovery but also the broader services and infrastructure that support drug development, such as data analysis and manufacturing processes. This trend may lead to new career opportunities in startups and industry, as well as more funding for translational research. The involvement of prominent investors and domain experts suggests that the field is attracting significant attention and resources.
Where to dig deeper
- Read the original report on techcrunch.com
- Track new papers on machine learning with Seamless
- Explore the backgrounds of startups like ChronicleBio and their approach to AI in healthcare
This article summarises public reporting. Facts as reported by techcrunch.com; read the original for full details.
